ClinicalTrials.gg
Active, not recruitingNCT06766929Updated May 4, 2026

A Phase I Clinical Study of VSA012 in Healthy Volunteers

A Phase 1 interventional study of VSA012 and Placebo in Healthy Volunteers, sponsored by Bisirna Therapeutics (Suzhou) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Bisirna Therapeutics (Suzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The complement system is an important component of the innate immune system. Abnormal activation, inadequate regulation and control of the complement system, as well as impaired and dysfunctional effector functions, underlie complement mediated diseases. VSA012 targeting complement system has the potential to treat a variety of diseases associated with abnormal activation of the complement system (e.g. PNH) .The purpose of VSA012-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VSA012 Injection in adult healthy volunteers (HVs). HVs will receive a single dose of VSA012 or placebo.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bisirna Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to provide written and to comply with study requirements
  • Participants must be non-pregnant/non-lactating
  • Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine.
  • (BMI) between 18.0 and 30.0 kg/m2
  • No abnormal finding of clinical relevance at the Screening evaluation that, in the opinion of the Investigator, could adversely impact participant safety or adversely impact study results.

Exclusion criteria

Exclusion Criteria:

  • History of recurrent or chronic infections including infections caused by encapsulated bacterial organisms or viruses
  • History of active bacterial, viral, or fungal infection within 14 days prior to treatment administrations
  • Seropositive for (HIV), virus (HBV) or virus (HCV)
  • History of meningococcal infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort1

    Drug: VSA012 · Drug: Placebo

  • Experimental
    Cohort2

    Drug: VSA012 · Drug: Placebo

  • Experimental
    cohort3

    Drug: VSA012 · Drug: Placebo

  • Experimental
    Cohort4

    Drug: VSA012 · Drug: Placebo

  • Experimental
    cohort5

    Drug: VSA012 · Drug: Placebo

Interventions

  • DrugVSA012

    VSA012 injection

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs)

    Time frame: up to Day 180

Secondary outcomes

  1. Pharmacokinetics (PK) of VSA012: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to 48 hours post-dose

  2. PK of VSA012: Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to 48 hours post-dose

  3. PK of VSA012: Area Under the Plasma Concentration Versus Time Curve

    Time frame: Up to 48 hours post-dose

  4. Change from Baseline in Serum Complement Factor B (CFB)

    Time frame: Up to Day 180

  5. Change from Baseline in Serum Complement Alternative Pathway (CAP)

    Time frame: up to Day 180

  6. The incidence of ADA

    Time frame: up to Day 180

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Aug 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2024
First posted
Jan 9, 2025
StartActual
Jan 20, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Jun 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06766929
Lead sponsor
Bisirna Therapeutics (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Jan 20, 2025
Primary completion
Aug 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VSA012

Start the discussion